IBM, CareKinesis, Coriell Life Sciences Launch Cloud-based Medication Risk Platform

IBM, Coriell Life Sciences and CareKinesis have launched a cloud-based service intended to analyze how high-risk individuals respond to specific medications and drug treatments.


IBM, Coriell Life Sciences and CareKinesis have launched a cloud-based service intended to analyze how high-risk individuals respond to specific medications and drug treatments.

In collaboration with IBM, Coriell Life Sciences built a cloud-based solution that stores data in Coriell Life Sciences' GeneVault. The GeneVault stores and manages millions of genetic data points. This data is then interpreted and shared with physicians through CareKinesis, which layers additional medication management decision factors into a tool for doctors within Corriell’s Program for All Inclusive Care of the Elderly organizations.

Physicians, healthcare providers and medical experts can access a patient's genomic interpretation via Web-connected device via the interfaced CareKinesis and Coriell Life Sciences systems.

For example, a cardiologist may consider prescribing a patient a popular blood-thinning drug, but may be concerned about the potential for an adverse reaction. The PACE team decides to conduct a test to assess if the participant will respond to the medication being considered. The test is run by swabbing the inside of the patient's cheek to collect a tiny amount of genetic material, which goes to Coriell Life Sciences for testing.

Results are analyzed and interpreted for their impact on drug response. The resulting report is then transmitted to the doctor giving guidance on whether the patient can safely use the drug. CareKinesis supports the process by making pharmacotherapy recommendations based on these results. The data can be used at any time it is needed in the future for pharmacotherapy prescribing decisions.

More for you

Loading data for hdm_tax_topic #better-outcomes...